Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in

  News Archive

Santhera Receives European Marketing Authorization for Raxone®
Thursday, September 10, 2015
First approved treatment for LHON and first approved treatment for a mitochondrial disease.

US FDA Grants Therapy Designation for Roche’s Investigational Medicine ACE910
Tuesday, September 08, 2015
First factor VIIIa-mimetic bispecific antibody to be investigated for the prophylactic treatment of haemophilia A.

Finding a Treatment for Parkinson's Disease Dementia
Tuesday, September 08, 2015
University of Adelaide neuroscientists are leading a world-first study into a form of dementia experienced by many Parkinson’s disease suffers, which is expected to ultimately lead to a new therapy for the condition.

Sanifit Raises €36.6M in Series C Financing Round
Tuesday, September 08, 2015
Financing will advance Sanifit’s lead drug candidate through phase IIb as a treatment for cardiovascular diseases linked to calcification and through phase II/III for calciphylaxis.

Novartis, Amgen Partner
Friday, September 04, 2015
The companies plan to co-develop and co-commercialize a BACE inhibitor program in Alzheimer's Disease (AD); Novartis' oral therapy CNP520 will be the lead molecule.

Santhera Receives Rare Pediatric Disease Designation from FDA
Tuesday, August 25, 2015
FDA has granted designation for idebenone for the treatment of Duchenne Muscular Dystrophy.

Medivation Acquires Talazoparib Rights from BioMarin
Tuesday, August 25, 2015
Under the agreement, Medivation will be responsible for all research, development, regulatory and commercialization activities for all indications on a global basis.

AstraZeneca, Peregrine Pharmaceuticals Collaborate
Tuesday, August 25, 2015
Collaboration to Focus on Cancer Immunotherapy Combination of Peregrine's PS-Targeting Bavituximab and AstraZeneca's PD-L1 Inhibitor MEDI4736.

EU Approves Novartis's laBCC Therapy
Monday, August 24, 2015
Novartis has announced that the European Commission has approved Odomzo® 200 mg capsules for the treatment of adult patients with locally advanced basal cell carcinoma (laBCC) who are not amenable to curative surgery or radiation therapy.

<< 3 4 5 6 7 8 9 >>
Showing Results 51 - 60 of 4159
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos